US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
EP2277551B1
(en)
|
2002-09-06 |
2013-05-08 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
ES2423060T3
(es)
*
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
WO2006017932A1
(en)
*
|
2004-08-18 |
2006-02-23 |
Genesense Technologies Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
NZ554214A
(en)
|
2004-09-24 |
2009-10-30 |
Alnylam Pharmaceuticals Inc |
Rnai modulation of apob and uses thereof
|
US7790878B2
(en)
*
|
2004-10-22 |
2010-09-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
KR101169668B1
(ko)
*
|
2005-01-07 |
2012-08-07 |
알닐람 파마슈티칼스 인코포레이티드 |
RSV의 RNAi 조절 및 이를 위한 약제학적 조성물
|
CA2594919A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of the nogo-l or nogo-r gene and uses thereof
|
ES2381201T3
(es)
*
|
2005-03-31 |
2012-05-24 |
Calando Pharmaceuticals, Inc. |
Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos
|
US7737265B2
(en)
*
|
2005-06-27 |
2010-06-15 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of HIF-1 and therapeutic uses thereof
|
WO2007011819A2
(en)
*
|
2005-07-15 |
2007-01-25 |
The Penn State Research Foundation |
Ferritin as a therapeutic target in abnormal cells
|
WO2007014075A2
(en)
*
|
2005-07-21 |
2007-02-01 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of the rho-a gene in research models
|
US7320965B2
(en)
|
2005-10-28 |
2008-01-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Huntingtin gene
|
WO2007056331A2
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
US8229398B2
(en)
*
|
2006-01-30 |
2012-07-24 |
Qualcomm Incorporated |
GSM authentication in a CDMA network
|
AU2007293169A1
(en)
*
|
2006-02-02 |
2008-03-13 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
BRPI0709147A2
(pt)
*
|
2006-03-24 |
2011-06-28 |
Novartis Ag |
composições de dsrna e métodos para tratamento de infecção por hpv
|
US7718629B2
(en)
|
2006-03-31 |
2010-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 gene
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
JP5570806B2
(ja)
|
2006-05-11 |
2014-08-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Pcsk9遺伝子の発現を阻害するための組成物および方法
|
US7888498B2
(en)
*
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
WO2008017473A2
(en)
|
2006-08-08 |
2008-02-14 |
Gunther Hartmann |
Structure and use of 5' phosphate oligonucleotides
|
WO2008026946A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Genesis Research And Development Corporation Limited |
Compositions and methods for the treatment and prevention of neoplastic disorders
|
AU2007299629C1
(en)
|
2006-09-21 |
2012-05-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the HAMP gene
|
EP2087115B1
(en)
*
|
2006-09-27 |
2012-11-21 |
Novarx |
Blocking of gene expression in eukaryotic cells
|
EP2125031B1
(en)
|
2006-12-19 |
2017-11-01 |
Marina Biotech, Inc. |
Lipids and lipid assemblies comprising transfection enhancer elements
|
CA2925983A1
(en)
|
2007-01-16 |
2008-07-24 |
The University Of Queensland |
Method of inducing an immune response
|
JP2010516625A
(ja)
|
2007-01-24 |
2010-05-20 |
インサート セラピューティクス, インコーポレイテッド |
制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
|
PE20090064A1
(es)
*
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
US7759320B2
(en)
|
2007-03-29 |
2010-07-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the Ebola
|
WO2008144365A2
(en)
*
|
2007-05-17 |
2008-11-27 |
Novartis Ag |
Method for making dry powder compositions containing ds-rna based on supercritical fluid technology
|
EP2848688A1
(en)
|
2007-12-10 |
2015-03-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
AU2008334948B2
(en)
|
2007-12-13 |
2014-11-20 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for prevention or treatment of RSV infection
|
WO2009137128A2
(en)
*
|
2008-02-12 |
2009-11-12 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd45 gene
|
JP2009203173A
(ja)
*
|
2008-02-26 |
2009-09-10 |
Hokkaido Univ |
siRNA−ポリカチオン複合体を含有するイオントフォレーシス用組成物
|
CN105267233B
(zh)
|
2008-03-05 |
2019-07-26 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
KR101713339B1
(ko)
|
2008-03-19 |
2017-03-08 |
차이나 신테틱 러버 코포레이션 |
간세포 암종의 진단 및 치료를 위한 방법 및 제제
|
AU2009232355A1
(en)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions and use of EPAS1 inhibitors
|
US7875711B2
(en)
|
2008-04-17 |
2011-01-25 |
Alnylam Pharamaceuticals, Inc. |
Compositions and methods for inhibiting expression of XBP-1 gene
|
CA2975841C
(en)
*
|
2008-04-30 |
2021-05-25 |
Siemens Medical Solutions Usa, Inc. |
Substrate based pet imaging agents
|
JP5689413B2
(ja)
|
2008-05-21 |
2015-03-25 |
ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン |
平滑末端を有する5’三リン酸オリゴヌクレオチドおよびその使用
|
US20110184046A1
(en)
|
2008-07-11 |
2011-07-28 |
Dinah Wen-Yee Sah |
Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
|
US8309791B2
(en)
*
|
2008-07-16 |
2012-11-13 |
Recombinectics, Inc. |
Method for producing a transgenic pig using a hyper-methylated transposon
|
US20100056475A1
(en)
*
|
2008-08-06 |
2010-03-04 |
Alexander Chucholowski |
Cyclodextrin conjugates
|
KR101661746B1
(ko)
|
2008-08-13 |
2016-09-30 |
캘리포니아 인스티튜트 오브 테크놀로지 |
캐리어 나노입자, 그리고 관련된 조성물, 방법 및 시스템
|
US20100068737A1
(en)
*
|
2008-09-16 |
2010-03-18 |
University Of Tennessee Research Foundation |
Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
|
EP2166076A1
(en)
*
|
2008-09-23 |
2010-03-24 |
The Procter & Gamble Company |
Cleaning composition
|
JP5529142B2
(ja)
|
2008-09-25 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法
|
EP2344638A1
(en)
|
2008-10-06 |
2011-07-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of an rna from west nile virus
|
EA020312B1
(ru)
|
2008-10-20 |
2014-10-30 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
WO2010046289A2
(en)
*
|
2008-10-22 |
2010-04-29 |
Universität Zürich Prorektorat Mnw |
BLOCKERS OF LIGHT, LTα1β2 AND LTα2β1 OR ITS RECEPTOR LTβR FOR THE PREVENTION AND TREATMENT OF CHRONIC HEPATITIS AND OTHER LIVER DISEASES
|
EP2346904B1
(en)
|
2008-10-29 |
2017-04-12 |
China Synthetic Rubber Corporation |
Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
CA2753703A1
(en)
|
2009-03-04 |
2010-09-10 |
Hirofumi Takeuchi |
Nucleic acid complex and nucleic acid-delivering composition
|
EP2406376A1
(en)
*
|
2009-03-12 |
2012-01-18 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
US20120004281A1
(en)
*
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
NZ597504A
(en)
*
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
EP2810643A3
(en)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
|
CN102639115A
(zh)
|
2009-09-15 |
2012-08-15 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物及抑制eg5和vegf基因的表达的方法
|
US9468650B2
(en)
|
2009-09-16 |
2016-10-18 |
Duke University |
Inhibition of endosomal toll-like receptor activation
|
WO2011038031A1
(en)
|
2009-09-22 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting sirna agents
|
EP2496238A4
(en)
|
2009-11-03 |
2013-10-02 |
Alnylam Pharmaceuticals Inc |
FORMULATED LIPID COMPOSITIONS AND METHODS FOR INHIBITING TRANSTHYRETIN EXPRESSION (TTR)
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
EP4385568A2
(en)
|
2010-04-06 |
2024-06-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
JP2013223426A
(ja)
*
|
2010-08-12 |
2013-10-31 |
Chugai Pharmaceut Co Ltd |
Rrm2のアンタゴニストを有効成分として含有するc型肝炎治療剤
|
WO2012056441A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
Compositions and methods for specific cleavage of exogenous rna in a cell
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
US8501930B2
(en)
*
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
KR102481317B1
(ko)
|
2011-03-29 |
2022-12-26 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
WO2012174224A2
(en)
*
|
2011-06-17 |
2012-12-20 |
Calando Pharmaceuticals, Inc. |
Methods for administering nucleic acid-based therapeutics
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
EP2723861A4
(en)
|
2011-06-21 |
2014-12-10 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
|
US9315813B2
(en)
|
2011-06-21 |
2016-04-19 |
Alnylam Pharmaceuticals, Inc |
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
ES2923573T3
(es)
|
2011-06-21 |
2022-09-28 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
EP2739735A2
(en)
|
2011-08-01 |
2014-06-11 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
KR102095699B1
(ko)
|
2011-11-18 |
2020-04-02 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
WO2014055493A1
(en)
|
2012-10-02 |
2014-04-10 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
HUE035887T2
(en)
|
2012-12-05 |
2018-05-28 |
Alnylam Pharmaceuticals Inc |
PCSK9 iRNA preparations and methods for their use
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
US9132097B2
(en)
|
2013-03-01 |
2015-09-15 |
California Institute Of Technology |
Nanoparticles stabilized with nitrophenylboronic acid compositions
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
SI2970974T1
(sl)
|
2013-03-14 |
2017-12-29 |
Alnylam Pharmaceuticals, Inc. |
Komplementarna komponenta C5 sestavkov IRNA in postopki njene uporabe
|
EP2978446B1
(en)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antibody for use in treating alzheimer's disease
|
CN113018307A
(zh)
|
2013-05-22 |
2021-06-25 |
阿尔尼拉姆医药品有限公司 |
SERPINA1 iRNA组合物及其使用方法
|
IL293657A
(en)
|
2013-05-22 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Preparations of tmprss6 irna and methods of using them
|
EP3052626A1
(en)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
PL3052628T3
(pl)
|
2013-10-04 |
2020-08-24 |
Alnylam Pharmaceuticals, Inc. |
Kompozycje i sposoby hamowania ekspresji genu ALAS1
|
US9493552B2
(en)
|
2013-11-15 |
2016-11-15 |
China Synthetic Rubber Corporation |
Therapeutic biologic for treatment of hepatocellular carcinoma
|
WO2015089368A2
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
JP6594902B2
(ja)
|
2014-02-11 |
2019-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物及びその使用方法
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
MX2016015126A
(es)
|
2014-05-22 |
2017-02-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
|
KR102631505B1
(ko)
|
2014-08-29 |
2024-02-01 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
EP3221451A1
(en)
|
2014-11-17 |
2017-09-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
EP3256587A2
(en)
|
2015-02-13 |
2017-12-20 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
CN115927335A
(zh)
|
2015-04-13 |
2023-04-07 |
阿尔尼拉姆医药品有限公司 |
类血管生成素3(ANGPTL3)iRNA组合物及其使用方法
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2017003668A1
(en)
|
2015-07-01 |
2017-01-05 |
California Institute Of Technology |
Cationic mucic acid polymer-based delivery systems
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
SG10201912341SA
(en)
|
2015-07-31 |
2020-02-27 |
Alnylam Pharmaceuticals Inc |
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스 감염에 대한 rnai 치료법
|
CN114939124A
(zh)
|
2015-08-25 |
2022-08-26 |
阿尔尼拉姆医药品有限公司 |
治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
|
JP7028764B2
(ja)
|
2015-09-02 |
2022-03-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プログラム細胞死1リガンド1(PD-L1)iRNA組成物およびその使用方法
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
JP7079495B2
(ja)
*
|
2015-12-25 |
2022-06-02 |
Sbiバイオテック株式会社 |
Tlr阻害性オリゴヌクレオチドおよびそれらの使用
|
US10154947B2
(en)
|
2016-01-06 |
2018-12-18 |
The Procter & Gamble Company |
Antiperspirant composition
|
US9730867B2
(en)
|
2016-01-06 |
2017-08-15 |
The Procter & Gamble Company |
Methods of forming a slurry with microcapsules formed from phosphate esters
|
US9732303B2
(en)
|
2016-01-06 |
2017-08-15 |
The Procter & Gamble Company |
Microcapsules formed from phosphate esters and compositions containing same
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
WO2018129261A1
(en)
|
2017-01-05 |
2018-07-12 |
Brown University |
Methods and compositions relating to anti-chi3l1 antibody reagents
|
JP7325045B2
(ja)
|
2017-02-27 |
2023-08-14 |
カイロス セラピューティクス, インコーポレイテッド |
癌を処置する抗体コンストラクトおよび方法
|
KR20200015895A
(ko)
|
2017-04-18 |
2020-02-13 |
알닐람 파마슈티칼스 인코포레이티드 |
B형 간염 바이러스 (hbv)에 감염된 대상체의 치료 방법
|
EP3619230A4
(en)
|
2017-05-01 |
2021-04-21 |
The Children's Medical Center Corporation |
METHODS AND COMPOSITIONS RELATING TO ANTI-PD1 ANTIBODY REAGENTS
|
JP7337044B2
(ja)
|
2017-07-13 |
2023-09-01 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Hao1(ヒドロキシ酸オキシダーゼ1(グリコール酸オキシダーゼ))遺伝子発現の阻害方法
|
AU2018301477A1
(en)
|
2017-07-13 |
2020-02-27 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
|
BR112020005230A2
(pt)
|
2017-09-19 |
2020-09-24 |
Alnylam Pharmaceuticals, Inc. |
composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
EP3714054A1
(en)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
BR112020012088A2
(pt)
|
2017-12-18 |
2020-11-17 |
Alnylam Pharmaceuticals, Inc. |
composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
|
KR102083478B1
(ko)
*
|
2017-12-28 |
2020-04-28 |
한양대학교 산학협력단 |
Chi3l1 억제제를 유효성분으로 하는 암의 폐 전이 예방 또는 치료용 약학 조성물
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
CA3099440A1
(en)
|
2018-06-13 |
2019-12-19 |
California Institute Of Technology |
Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
|
TW202020157A
(zh)
|
2018-08-16 |
2020-06-01 |
美商艾爾妮蘭製藥公司 |
用於抑制lect2基因表現之組合物及方法
|
JP2022500003A
(ja)
|
2018-09-18 |
2022-01-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
WO2020132521A1
(en)
|
2018-12-20 |
2020-06-25 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
LT3897672T
(lt)
|
2018-12-20 |
2023-11-10 |
Vir Biotechnology, Inc. |
Kombinuota hbv terapija
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4007811A2
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
|
EP4013870A1
(en)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
|
EP4025694A1
(en)
|
2019-09-03 |
2022-07-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EP4041894A1
(en)
|
2019-09-23 |
2022-08-17 |
Omega Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
EP4041308A1
(en)
|
2019-10-07 |
2022-08-17 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
WO2021081026A1
(en)
|
2019-10-22 |
2021-04-29 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
EP4051796A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
AU2020376840A1
(en)
|
2019-11-01 |
2022-04-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (HTT) iRNA agent compositions and methods of use thereof
|
KR20220115946A
(ko)
|
2019-11-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
|
US20230056569A1
(en)
|
2019-11-22 |
2023-02-23 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
MX2022006433A
(es)
|
2019-12-13 |
2022-06-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72) y metodos de uso de los mismos.
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP4093426A1
(en)
|
2020-01-24 |
2022-11-30 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Preparations and methods for silencing vegf-a expression
|
IL295496A
(en)
|
2020-02-18 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Apolipoprotein c3 (apoc3) irna preparations and methods of using them
|
CN115485383A
(zh)
|
2020-03-06 |
2022-12-16 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
EP4118207A1
(en)
|
2020-03-11 |
2023-01-18 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
BR112022020145A2
(pt)
|
2020-04-06 |
2023-01-03 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciamento da expressão de myoc
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
EP4133079A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
AU2021263554A1
(en)
|
2020-04-27 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein E (APOE) iRNA agent compositions and methods of use thereof
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
EP4168546A1
(en)
|
2020-06-18 |
2023-04-26 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
BR112022026316A2
(pt)
|
2020-06-24 |
2023-03-07 |
Vir Biotechnology Inc |
Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
EP4225917A1
(en)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
AU2021365822A1
(en)
|
2020-10-21 |
2023-06-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
IL302709A
(en)
|
2020-11-13 |
2023-07-01 |
Alnylam Pharmaceuticals Inc |
Coagulation factor iRNA compositions (F5) and methods of using them
|
TW202237150A
(zh)
|
2020-12-01 |
2022-10-01 |
美商艾拉倫製藥股份有限公司 |
用於抑制hao1(羥基酸氧化酶1(乙醇酸氧化酶))基因表現的方法及組成物
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
WO2022147009A1
(en)
*
|
2020-12-29 |
2022-07-07 |
Precise-Therapeutics Llc |
Compositions and associated methods for sustained-release of radioactive agents and their applications
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
US20240117033A1
(en)
|
2021-01-15 |
2024-04-11 |
President And Fellows Of Harvard College |
Methods and compositions relating to anti-mfsd2a antibodies
|
IL304880A
(en)
|
2021-02-12 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Superoxide dismutase 1 (SOD1) IRNA compositions and methods of using them to treat or prevent superoxide dismutase 1- (SOD1-) associated neurodegenerative diseases
|
EP4298220A1
(en)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods of use thereof
|
IL305153A
(en)
|
2021-02-26 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Ketohexokinase (KHK) iRNA compositions and methods of using them
|
WO2022187435A1
(en)
|
2021-03-04 |
2022-09-09 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
IL307239A
(en)
|
2021-03-29 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
JP2024517686A
(ja)
|
2021-04-26 |
2024-04-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
膜貫通プロテアーゼ、セリン6(TMPRSS6)iRNA組成物およびその使用方法
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法
|
JP2024522068A
(ja)
|
2021-05-18 |
2024-06-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
BR112023025224A2
(pt)
|
2021-06-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
|
WO2022260939A2
(en)
|
2021-06-08 |
2022-12-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
KR20240026203A
(ko)
|
2021-06-30 |
2024-02-27 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
IL309897A
(en)
|
2021-07-21 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Target gene IRNA compositions associated with a metabolic disorder and methods of using them
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
CN117795074A
(zh)
|
2021-08-03 |
2024-03-29 |
阿尔尼拉姆医药品有限公司 |
转甲状腺素蛋白(TTR)iRNA组合物和其使用方法
|
IL310295A
(en)
|
2021-08-04 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
iRNA compositions and methods for silencing angiotensinogen (AGT)
|
IL310407A
(en)
|
2021-08-13 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Factor XII (F12) IRNA compositions and methods of using them
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
IL311864A
(en)
|
2021-10-15 |
2024-06-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions for extrahepatic administration and methods of using them
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023138211A1
(zh)
*
|
2022-01-21 |
2023-07-27 |
苏州万维生命科学技术有限公司 |
星型β-抗菌糖肽、其制备方法及应用
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024119145A1
(en)
|
2022-12-01 |
2024-06-06 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|